Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid-use Disorder
Interventions: Telemedicine Linkage Intervention; Behavioral
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: Lumateperone Long-Acting Injectable; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions: Gamunex-C; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: ACL, Postoperative Pain
Interventions: Exparel 30 mL, 0.5% bupivacaine, Dexamethasone, iPACK block; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), Keyhole-Limpet Hemocyanin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Chronic Pancreatitis, Pancreatic Cancer
Interventions: one injection into the celiac ganglion, two injections into the celiac ganglion; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Osteoarthritis
Interventions: RTX-GRT7039; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 27
States / cities: Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 24 more

Conditions: Opiate Dependence
Interventions: Linkage; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 17 more

Conditions: Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions: Aflibercept; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Lexington, Kentucky • Nashville, Tennessee

Conditions: Cosmetic Techniques
Interventions: Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nail Psoriasis
Interventions: Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Methotrexate (MTX); Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017 (peginterferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more

Conditions: Multiple Sclerosis
Interventions: RebiSmart™; Device
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo; Biological · Dietary Supplement
Lead sponsor: Diamyd Medical AB; Industry
Eligibility: 12 Years to 28 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Newport Beach, California • Palo Alto, California • San Diego, California + 10 more

Conditions: Diabetic Macular Edema
Interventions: iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Retinal Disease
Interventions: IRX-101, Providone-Iodine; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 107
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more

Conditions: Advanced Solid Tumor
Interventions: STX-001, Keytruda®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more

Conditions: Lumbar Spine Disc Herniation
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

SAD and MAD Study of FTX-101 in Healthy Male Subjects

Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Exparel vs Block for ACL Reconstruction

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

Prospective Study of Celiac Block Injection: 1 vs. 2

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Linking Hospitalized Injection Drug Users to Buprenorphine

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Local Methotrexate Injections for the Treatment of Nail Psoriasis

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?